...
首页> 外文期刊>Asian Pacific Journal of Cancer Prevention >Radioimmunoimaging with Mixed Monoclonal Antibodies of Nude Mice Bearing Human Lung Adenocarcinoma Xenografts
【24h】

Radioimmunoimaging with Mixed Monoclonal Antibodies of Nude Mice Bearing Human Lung Adenocarcinoma Xenografts

机译:带有人肺腺癌异种移植裸鼠的混合单克隆抗体的放射免疫成像

获取原文

摘要

The present study was conducted to evaluate radioimmunoimaging (RII) and in vivo distribution of mixedantibodies 99mTc-EGFR-mAb and 99mTc-CD44- mAb in nude mice bearing human lung adenocarcinoma xenografts.Single and mixed applications of the two radiolabeled monoclonal antibodies (mAbs) were compared. Directlabeling of 99mTc was applied to radiolabel the EGFR and CD44 mAbs. The properties of the radiolabeledantibodies were then characterized. RII and assessment of the distribution of the antibodies in nude mice bearinglung adenocarcinoma xenografts were achieved by applying separate and combined doses of 99mTc-EGFR-mAband 99mTc-CD44-mAb. The labeling rates of 99mTc for EGFR-mAb and CD44-mAb were 91.5% ± 3.8% and 92.3%± 4.1% respectively, with specific activities of 2.8 and 2.9 MBq/μg, respectively, and radiochemical purities (RCP)of 96.5% and 96.2%. The radioactivity uptake of the combined application of both radiolabeled antibodieswas clearly higher than with a single application of either alone. The relative values of target-to-nontarget (T/NT) measured through the regional interest (ROI) technique were 5.59 ± 0.42 (mixed antibodies), 2.78 ± 0.20(99mTc-EGFR-mAb), and 2.28 ± 0.16 (99mTc-CD44-mAb) in the RII. The body distribution of the radiolabeledantibodies and their imaging results were basically identical. Application of the mixed antibodies with 99mTc-EGFR-mAb and 99mTc-CD44-mAb can increase the radioactivity uptake of tumor tissue, leading to more idealtarget-to-nontarget ratios, and therefore superior results.
机译:本研究旨在评估携带人肺腺癌异种移植物的裸鼠的放射免疫成像(RII)和混合抗体99mTc-EGFR-mAb和99mTc-CD44-mAb在体内的分布。两种放射标记的单克隆抗体(mAbs)的单次和混合应用比较。将99mTc直接标记用于放射性标记EGFR和CD44 mAb。然后表征放射性标记的抗体的性质。通过应用单独和联合剂量的99mTc-EGFR-mAband 99mTc-CD44-mAb,可以实现RII和抗体在携带肺腺癌异种移植的裸鼠中抗体分布的评估。 EGFR-mAb和CD44-mAb的99mTc标记率分别为91.5%±3.8%和92.3%±4.1%,比活分别为2.8和2.9 MBq /μg,放射化学纯度(RCP)为96.5%和96.2%。两种放射性标记抗体联合应用的放射性吸收明显高于单独使用两种抗体。通过区域兴趣(ROI)技术测得的靶标与非靶标(T / NT)的相对值为5.59±0.42(混合抗体),2.78±0.20(99mTc-EGFR-mAb)和2.28±0.16(99mTc- RII中的CD44-mAb)。放射性标记抗体的体内分布及其成像结果基本相同。混合抗体与99mTc-EGFR-mAb和99mTc-CD44-mAb的应用可以增加肿瘤组织的放射性吸收,从而导致更理想的靶标与非靶标比率,因此效果更佳。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号